Lakewood-Amedex Biotherapeutics Inc. (LABT) Form 424B3 — Jun 22, 2026
Lakewood-Amedex Biotherapeutics Inc. has filed a Certificate of Change to effect a 1-for-10 reverse stock split of its common stock, approved by the Board on June 1, 2026. The reverse split will reduce the number of issued and outstanding shares from approximately 17.5 million to approximately 1.75 million. The reverse split becomes effective at 4:01 p.m.
Key figures
- Par value
- $0.0001
- Pre split shares
- 17,506,577
- Post split shares
- 1,750,789
- Reverse split ratio
- 1-for-10
- Authorized shares post split
- 12,500,000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.